Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pasta

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 10, 2025
Real-world association between ivacaftor initiation and lung function variability: A registry studyRhonda D Szczesniak, Eleni-Rosalina Andrinopoulou, Hancheng Li, et al.
Chest|February 18, 2019
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment StrategiesRaymond L Benza, Mardi Gomberg-Maitland, C Greg Elliott, et al.
The Journal of Pediatrics|July 24, 2007
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosisMichael W Konstan, Wayne J Morgan, Steven M Butler, et al.
Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.
Annals of the American Thoracic Society|March 8, 2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical InterpretationsRhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 10, 2025
Real-world association between ivacaftor initiation and lung function variability: A registry studyRhonda D Szczesniak, Eleni-Rosalina Andrinopoulou, Hancheng Li, et al.
Chest|February 18, 2019
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment StrategiesRaymond L Benza, Mardi Gomberg-Maitland, C Greg Elliott, et al.
The Journal of Pediatrics|July 24, 2007
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosisMichael W Konstan, Wayne J Morgan, Steven M Butler, et al.
Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.
Annals of the American Thoracic Society|March 8, 2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical InterpretationsRhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, et al.
Pageof 10